<DOC>
	<DOCNO>NCT02854605</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability GS-9674 participant nonalcoholic steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>Evaluating Safety , Tolerability , Efficacy GS-9674 Participants With Nonalcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Meets follow condition : A clinical diagnosis nonalcoholic fatty liver disease ( NAFLD ) Screening magnetic resonance image proton density fat fraction ( MRIPDFF ) ≥ 8 % steatosis Screening magnetic resonance elastography ( MRE ) liver stiffness ≥ 2.5 kilopascal ( kPa ) OR A historical liver biopsy within 12 month screen consistent NASH fibrosis , cirrhosis , No document weight loss &gt; 5 % date liver biopsy screening . Platelet count ≥ 150,000/mm^3 Albumin ≥ 3.3 g/dL Serum creatinine ≤ upper limit normal ( ULN ) Key Pregnant lactate female Alanine aminotransferase ( ALT ) &gt; 5x upper limit normal range ( ULN ) Other cause liver disease include autoimmune , viral , alcoholic liver disease Cirrhosis liver Prior history decompensated liver disease , include ascites , hepatic encephalopathy , variceal bleed Body mass index ( BMI ) &lt; 18 kg/m^2 Uncontrolled diabetes mellitus ( hemoglobin A1c &gt; 9 % screening ) International normalize ratio ( INR ) &gt; 1.2 unless anticoagulant therapy Total bilirubin &gt; 1 x ULN , except diagnosis Gilbert 's syndrome NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-alcoholic fatty liver disease ( NAFLD )</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>GS-9674</keyword>
</DOC>